|
1
|
Reiners C, Hӓnscheid H, Luster M, Lassmann
M and Verburg FA: Radioiodine for remnant ablation and therapy of
metastatic disease. Nat Rev Endocrinol. 7:589–595. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Biondi B, Pulcrano M, Pagano L and
Lombardi G: Adjuvant treatment with thyrotropin alpha for remnant
ablation in thyroid cancer. Biologics. 3:9–13. 2009.PubMed/NCBI
|
|
3
|
Klein HA: Radioiodine dilution due to
levothyroxine when using recombinant human thyroid-stimulating
hormone: case report and discussion. Clin Nucl Med. 36:899–903.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klubo-Gwiezdzinska J, Burman KD, Van
Nostrand D, Mete M, Jonklaas J and Wartofsky L: Radioiodine
treatment of metastatic thyroid cancer: relative efficacy and side
effect profile of preparation by thyroid hormone withdrawal versus
recombinant human thyrotropin. Thyroid. 22:310–317. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luster M, Lippi F, Jarzab B, Perros P,
Lassmann M, Reiners C and Pacini F: rhTSH-aided radioiodine
ablation and treatment of differentiated thyroid carcinoma: a
comprehensive review. Endocr Relat Cancer. 12:49–64. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tuttle RM, Lopez N, Leboeuf R, et al:
Radioactive iodine administered for thyroid remnant ablation
following recombinant human thyroid stimulating hormone preparation
also has an important adjuvant therapy function. Thyroid.
20:257–263. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cooper DS, Doherty GM, Haugen BR, et al:
Management guidelines for patients with thyroid nodules and
differentiated thyroid cancer. Thyroid. 16:109–142. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pacini F, Schlumberger M, Dralle H, et al:
European consensus for the management of patients with
differentiated thyroid carcinoma of the follicular epithelium. Eur
J Endocrinol. 154:787–803. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mazzaferri EL and Kloos RT: Clinical
review 128: Current approaches to primary therapy for papillary and
follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schroeder PR, Haugen BR, Pacini F, et al:
A comparison of short-term changes in health-related quality of
life in thyroid carcinoma patients undergoing diagnostic evaluation
with recombinant human thyrotropin compared with thyroid hormone
withdrawal. J Clin Endocrinol Metab. 91:878–884. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McLeod DS: Current concepts and future
directions in differentiated thyroid cancer. Clin Biochem Rev.
31:9–19. 2010.PubMed/NCBI
|
|
12
|
Elisei R, Schlumberger M, Driedger A, et
al: Follow-up of low-risk differentiated thyroid cancer patients
who underwent radioiodine ablation of postsurgical thyroid remnants
after either recombinant human thyrotropin or thyroid hormone
withdrawal. J Clin Endocrinol Metab. 94:4171–4179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Phan HT, Jager PL, van der Wal JE, et al:
The follow-up of patients with differentiated thyroid cancer and
undetectable thyroglobulin (Tg) and Tg antibodies during ablation.
Eur J Endocrinol. 158:77–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Meer SG, Vriens MR, Zelissen PM, Borel
Rinkes IH and de Keizer B: The role of routine diagnostic
radioiodine whole-body scintigraphy in patients with high-risk
differentiated thyroid cancer. J Nucl Med. 52:56–59. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Enewold L, Zhu K, Ron E, Marrogi AJ,
Stojadinovic A, Peoples GE and Devesa SS: Rising thyroid cancer
incidence in the United States by demographic and tumor
characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev.
18:784–791. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tuttle RM, Leboeuf R and Martorella AJ:
Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab
Clin North Am. 36:753–778. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jonklaas J, Sarlis NJ, Litofsky D, et al:
Outcomes of patients with differentiated thyroid carcinoma
following initial therapy. Thyroid. 16:1229–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gosnell JE and Clark OH: Surgical
approaches to thyroid tumors. Endocrinol Metab Clin North Am.
37:437–455. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Nostrand D and Wartofsky L:
Radioiodine in the treatment of thyroid cancer. Endocrinol Metab
Clin North Am. 36:807–822. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sawka AM, Brierley JD, Tsang RW, et al: An
updated systematic review and commentary examining the
effectiveness of radioactive iodine remnant ablation in
well-differentiated thyroid cancer. Endocrinol Metab Clin North Am.
37:457–480. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brierley J, Tsang R, Panzarella T and Bana
N: Prognostic factors and the effect of treatment with radioactive
iodine and external beam radiation on patients with differentiated
thyroid cancer seen at a single institution over 40 years. Clin
Endocrinol (Oxf). 63:418–427. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Biondi B, Filetti S and Schlumberger M:
Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat
Clin Pract Endocrinol Metab. 1:32–40. 2005. View Article : Google Scholar : PubMed/NCBI
|
